21 October 2014, Sydney, Australia:Viralytics Limited (ASX: VLA, OTC: VRACY) will participate later today at the 5thAnnual Australian Microcap Conference in Melbourne.

Managing Director Dr Malcolm McColl will present at the event at 12.15pm.

"Viralytics is pleased to be able to showcase the company's recent achievements, present an update on the further clinical development of CAVATAK, and describe the substantial potential market opportunity for new agents in the cancer immunotherapy field" said Dr McColl.

The event is the largest in Australia focussing on the microcap sector and will be attended by representatives from over 130 investor groups.

The presentation, which is linked below, outlines CAVATAK's potential in a range of cancer types and provides an update on the company's clinical trial programme, specifically:

· the successful Phase 2 CALM trial in melanoma patients in the US;
· the Phase 1 / 2 STORM trial in solid cancer patients underway in the UK;
· plans for combination trials involving CAVATAK in late stage melanoma patients; and
· an upcoming Phase 1 clinical trial in non-muscle invasive bladder cancer patients in the UK.

Investor Presentation link:http://www.asx.com.au/asxpdf/20141021/pdf/42t1gmlk52lxll.pdf

Enquiries
Dr Malcolm McColl Mr Rudi Michelson
Chief Executive Officer Monsoon Communications
02 9988 4000 03 9620 3333

To continue reading this noodl, please get the original version here.

distributed by